Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
You might be tempted to gatekeep, but that would be downright cruel.
ALA STUDENT MEMBERS ATTEND FREE! NOT AN ALA STUDENT MEMBER? JOIN ALA TODAY AND ATTEND FOR FREE! Email your Purchase Order registration request to registration@ala.org.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results